← back to search

Jerill Thorpe

Bristol-Myers Squibb (United States) · GB
Area of research
Oncology · Immunology
Research interest
Research interests include CAR-T cell therapy research, T-cell and B-cell Immunology, Chronic Lymphocytic Leukemia Research, and Immune Cell Function and Interaction.
h-index
14
citations
1,318
works
39
NIH funding
primary concept
Medicine
email

Recent publications

Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study
Blood Advances 2025cited by 9position: middledoi
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma
Leukemia 2025cited by 6position: middledoi
Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study
Blood 2023cited by 15position: middledoi
Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Blood 2022cited by 39position: middledoi
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
Blood 2021cited by 119position: middledoi
Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Blood 2020cited by 53position: middledoi
A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI)
Cytometry Part A 2013cited by 65position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

K. OGASAWARA · Bristol-Myers Squibb (United States)4 papers (2020–2025)Peter A. Riedell · Janssen (United States)3 papers (2021–2025)Scott R. Solomon · Leukemia Research Foundation3 papers (2020–2025)Ashley K. Koegel · Bristol-Myers Squibb (United States)2 papers (2022–2025)Lucy Gong · National Eczema Association2 papers (2020–2021)Deborah M. Stephens · University of North Carolina at Chapel Hill2 papers (2020–2021)Kathleen Dorritie · University of Pittsburgh2 papers (2020–2021)Shebli Atrash · Levine Cancer Institute2 papers (2022–2025)Shambavi Richard · Icahn School of Medicine at Mount Sinai2 papers (2022–2025)James Essell · Oncology Hematology Care2 papers (2023–2025)Kristen Hege · Independent Sector2 papers (2022–2025)Alison R. Sehgal · UPMC Hillman Cancer Center2 papers (2023–2025)John E. Godwin · University of Western States2 papers (2023–2025)Gurbakhash Kaur · Southwestern Medical Center2 papers (2022–2025)Benjamin A. Derman · Comprehensive Cardiovascular2 papers (2022–2025)Sham Mailankody · Weill Cornell Medicine2 papers (2022–2025)Michael R. Burgess · Bristol-Myers Squibb (United States)2 papers (2022–2025) · 2 papers (2022–2025)Nilanjan Ghosh · Wake Forest Baptist Comprehensive Cancer Center2 papers (2023–2025) · 2 papers (2022–2025)